Genetically modified non-human animal with human or chimeric SIRPa
The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) SIRPα, and methods of use thereof.
1. A genetically-modified mouse whose genome comprises a chimeric SIRPα gene encoding a chimeric SIRPα protein, wherein the chimeric SIRPα gene comprises a replacement of a portion of mouse SIRPα gene exon 2 with a portion of human SIRPα gene exon 3, wherein the chimeric SIRPα gene further comprises mouse SIRPα gene exon 3 and mouse SIRPα gene exon 4, wherein the mouse expresses the chimeric SIRPα protein.
2. The mouse of claim 1 , wherein the genome of the mouse comprises the chimeric SIRPα gene at an endogenous SIRPα gene locus, wherein the chimeric SIRPα gene is operably linked to an endogenous regulatory element at the endogenous SIRPα gene locus.
3. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is at least 70% identical to SEQ ID NO: 8, 25, 26, 27, or 28.
4. The mouse of claim 1 , wherein the chimeric SIRPα protein comprises a sequence that is at least 90% identical to amino acids 31-138 of SEQ ID NO: 4.
5. The mouse of claim 1 , wherein the mouse does not express endogenous SIRPα protein.
6. The mouse of claim 1 , wherein the mouse is homozygous with respect to the chimeric SIRPα gene.
7. The mouse of claim 1 , wherein the mouse further comprises a sequence encoding a human or humanized CD47.
8. The mouse of claim 1 , wherein exon 2 at the endogenous SIRPα gene locus is modified by CRISPR with sgRNAs that target SEQ ID NO: 44 and SEQ ID NO: 54.
9. A genetically modified mouse or a progeny thereof, wherein the genetically modified mouse is made by a method comprising the steps of:
modifying genome of a fertilized egg or an embryo of a mouse by CRISPR with sgRNAs that target a 5′-terminal targeting site and a 3′-terminal targeting site, wherein the 5′ -terminal targeting site is selected from the group consisting of target SEQ ID NOS: 39-47 and the 3′-terminal targeting site is selected from the group consisting of SEQ ID NOS: 48-58, wherein an endogenous SIRPα gene locus in the genome of the fertilized egg or the embryo is modified; and
transplanting the fertilized egg or the embryo to a recipient mouse to produce the genetically-modified mouse.
10. The generically-modified mouse of claim 9 , wherein the 5′-terminal targeting site is SEQ ID NO: 44 and the 3′-terminal targeting site is SEQ ID NO: 54.
11. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 8.
12. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 25.
13. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 26.
14. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 27.
15. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 28.
16. The mouse of claim 1 , wherein at least 100 contiguous nucleotides in mouse SIRPα gene exon 2 are replaced by at least 100 contiguous nucleotides in human SIRPα gene exon 3.
17. The mouse of claim 1 , wherein at least 200 contiguous nucleotides in mouse SIRPα gene exon 2 are replaced by at least 200 contiguous nucleotides in human SIRPα gene exon 3.
18. The mouse of claim 1 , wherein at least 300 contiguous nucleotides in mouse SIRPα gene exon 2 are replaced by at least 300 contiguous nucleotides in human SIRPα gene exon 3.
19. The mouse of claim 1 , wherein the chimeric SIRPα gene encodes an amino acid sequence that is identical to SEQ ID NO: 8.